Diffusion Pharmaceuticals is a drug-discovery and development company, engages in the commercialization of small-molecule therapeutics to treat serious or life-threatening medical conditions by increasing the amount of oxygen to hypoxic tissues. Its products include trans sodium crocetinate and trans bipolar carotenoids molecules, which are used to treat life-threatening conditions, such as trauma, cancer, stroke, cardiovascular diseases, respiratory disorders, peripheral vascular and arterial diseases, and various other conditions.
Type
Public
HQ
Charlottesville, US
Founded
2001
Size (employees)
10 (est)
Diffusion Pharmaceuticals was founded in 2001 and is headquartered in Charlottesville, US
Report incorrect company information

Key People/Management at Diffusion Pharmaceuticals

David Kalergis

David Kalergis

Chairman & Chief Executive Officer
Ben Shealy

Ben Shealy

CFO
David Jones

David Jones

Chief Medical Officer
John Gainer

John Gainer

Chief Scientific Officer
Show more

Diffusion Pharmaceuticals Office Locations

Diffusion Pharmaceuticals has an office in Charlottesville
Charlottesville, US (HQ)
400 1317 Carlton Ave
Show all (1)
Report incorrect company information

Diffusion Pharmaceuticals Financials and Metrics

Diffusion Pharmaceuticals Revenue

USD

Net income (FY, 2017)

(1.4 m)

EBIT (FY, 2017)

(11.3 m)

Market capitalization (20-Jul-2018)

23.4 m

Closing stock price (20-Jul-2018)

0.5

Cash (31-Dec-2017)

8.9 m

EV

15 m
Diffusion Pharmaceuticals's current market capitalization is $23.4 m.
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

2.5 m11.1 m6.2 m

R&D expense

3.9 m7.3 m5.1 m

Operating expense total

6.4 m18.3 m11.3 m
USDFY, 2015FY, 2016FY, 2017

Cash

2 m1.6 m8.9 m

Prepaid Expenses

45.9 k50.8 k769.9 k

Current Assets

2 m1.6 m9.7 m

PP&E

52 k79.8 k460.7 k
USDFY, 2015FY, 2016FY, 2017

Net Income

(6.7 m)(18 m)(1.4 m)

Depreciation and Amortization

8.3 k25.3 k68 k

Accounts Payable

647.6 k991.6 k(1.7 m)

Cash From Operating Activities

(5.2 m)(10.8 m)(12.3 m)
USDY, 2017

EV/EBIT

-1.3 x

EV/CFO

-1.2 x

Financial Leverage

1.2 x

P/E Ratio

(0.2 )
Show all financial metrics
Report incorrect company information

Diffusion Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Diffusion Pharmaceuticals Company Life and Culture

Report incorrect company information